LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Olivia Manser
+44 (0) 7780 471568
This email address is being protected from spambots. You need JavaScript enabled to view it.

Julia Wilson
+44 (0) 7818 430877 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303 
This email address is being protected from spambots. You need JavaScript enabled to view it.